Ac immune presents new preclinical data for therapeutic and diagnostic candidates addressing novel targets for neurodegenerative diseases

Four presentations at ad/pd™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and tdp-43

ACIU Ratings Summary

ACIU Quant Ranking